Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination
Guangzhou Medical University & AstraZeneca: Advancing understanding of COPD in China
An IMED Collaboration Update
We’re working with Guangzhou Medical University, one of the world’s leading centres for research into respiratory disease, to advance the scientific understanding of Chronic Obstructive Pulmonary Disease (COPD). Our team had previously carried out COPD studies in many western countries and was interested in comparing earlier findings with those from China, where COPD prevalence is high and rising rapidly. Our aim is to find better ways of diagnosing and preventing incidence.Download collaboration update (PDF 260kb)
All Directors are collectively responsible for the success of AstraZeneca. Discover general information, images and biographies of our Board of Directors.
AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.
Path to new medicines
The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.
Visit our dedicated neuroscience site for more information on our research and partnering in the area.
Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines